Portland General Electric Company (NYSE:POR) shares fell -4.52% in last trading session and ended the day at $35.46. POR Gross Margin is 61.00% and its has a return on assets of 2.30%. Portland General Electric Company (NYSE:POR) quarterly performance is -1.38%.
Portland General Electric Company (NYSE: POR) reported net income of $36 million, or 40 cents per diluted share, for the third quarter of 2015. This compares with net income of $39 million, or 47 cents per diluted share, for the third quarter of 2014. The net annual revenue requirement increase of $13 million, or 0.7%, will be effective in two phases. A $43 million decrease, representing a 2.4% decrease in customer prices effective January 1, 2016, will consist of a reduction in base business costs of $15 million and a decrease of $28 million related to the amortization of certain customer credits through supplemental tariffs. A $56 million annualized increase, representing a customer price increase of 3.1%, will be effective when Carty becomes operational, provided that occurs by July 31, 2016.
Reliv’ International, Inc. (NASDAQ:RELV) ended the last trading day at $0.69. Company weekly volatility is calculated as 11.23% and price to cash ratio as 1.95.
Reliv’ International, Inc. (NASDAQ:RELV) reported its financial results for the second quarter of 2015. Net sales for the quarter were $12.4 million, a 14.0 percent decrease from the second quarter last year. Net U.S. sales totaled $9.6 million, down from $10.8 million in the second quarter of 2014. Net sales outside of the United States decreased 22.1 percent in the second quarter of 2015 compared to the prior-year quarter. Foreign currency fluctuation accounted for 8.7 percent of the net sales decline outside of the United States. Net sales in Europe declined 30.7 percent in the second quarter of 2015 compared to the prior-year quarter, with foreign currency fluctuation accounting for 6.8 percent of the decline.
On 06 November, NIKE, Inc. (NYSE:NKE) shares fell -0.06% and was closed at $131.78. NKE EPS growth in last 5 year was 13.90%. NIKE, Inc. (NYSE:NKE) year to date (YTD) performance is 38.18%.
NIKE, Inc. (NYSE:NKE) wants to kickLululemon’s legging-clad posterior in the fight for global domination of women’s athletic apparel.Nike, the world’s largest sports apparel brand known for its “Just Do It” grit, powerhouse marketing abilities and backing of some of the most famous pro athletes, has its sights set on courting recreational female athletes. It joins the crush of apparel marketers targeting the female athletic wear buyer and capitalizing on the functional-yet-fashionable fitness-wear trend known as athleisure.Last month, during an investor conference here, Nike said it expects revenue in its woman’s category to rise from $5.7 billion to more than $11 billion in the next five years. It will use that growth to fuel an even loftier goal: to generate $50 billion in overall sales by 2020.
Iconix Brand Group, Inc. (NASDAQ:ICON) shares fell -57.25% in last trading session and ended the day at $6.90. And its has a return on assets of 4.60%. Iconix Brand Group, Inc. (NASDAQ:ICON) quarterly performance is -52.64%.
Iconix Brand Group, Inc. (Nasdaq: ICON) announced that the Company intends to restate certain of its historical financial statements. The Company also announced preliminary third quarter 2015 results and updated guidance for the full year 2015. As previously announced, the Company will hold a conference call on Monday, November 9, 2015 at 8:30 AM ET to discuss its third quarter results. The Company will also discuss the restatement at that time, as well as provide guidance for 2016.
XOMA Corporation (NASDAQ:XOMA) caters to the Healthcare space. Its weekly performance is 0.82%. On the last day of trading company shares ended up at $1.23. XOMA Corporation (NASDAQ:XOMA) distance from 50-day simple moving average (SMA50) is -5.10%.
XOMA Corporation (Nasdaq:XOMA), provided a corporate update and reported its financial results for the quarter ended September 30, 2015. XOMA reported total revenues of $2.1 million in the third quarter ended September 30, 2015, compared with $5.1 million in the corresponding period of 2014. The 2015 revenues reflect lower activity under the Company’s existing contracts with National Institute of Allergy and Infectious Diseases (NIAID) for the development of anti-botulism agents, lower reimbursements from Servier for gevokizumab-related expenses, and lower milestone payments received in 2015 as compared with 2014.
Leave a Reply